Table 2 Characteristics of nr-axSpA patients at initiation of first TNFi treatment after exclusion of patients with co-morbid fibromyalgia
Parameter | N, 163 | Men, N = 78 | Women, N = 85 | p |
|---|---|---|---|---|
Age, years | 163 | 35.6 (10.8) | 39.1 (11.4) | 0.10 |
Age at onset, years | 162 | 27.9 (8.6) | 28.1 (8.5) | 0.66 |
Symptom duration, years | 163 | 7.6 (8.8) | 10.9 (10.8) | 0.05 |
Diagnostic delay, years | 162 | 4.1 (7.6) | 7.8 (9.9) | 0.005 |
HLA-B27 positive, % | 149 | 75.7 | 68.0 | 0.36 |
Prior sacroiliitis on MRI, % | 154 | 70.8 | 68.3 | 0.86 |
BASDAI | 148 | 5.3 (2.0) | 6.3 (1.6) | 0.003 |
Physician Global Assessment | 155 | 5.0 (1.9) | 4.8 (1.6) | 0.63 |
Patient Global Assessment | 149 | 6.4 (2.2) | 6.7 (2.1) | 0.30 |
ASDAS | 140 | 3.3 (1.0) | 3.4 (0.7) | 0.29 |
ASDAS > 2.1, % | 140 | 83.9 | 96.2 | 0.02 |
CRP (mg/l), median (IQR) | 154 | 6.0 (2.0; 12.0) | 5.0 (3.0; 9.0) | 0.43 |
Elevated CRP, % | 154 | 42.5 | 38.3 | 0.62 |
BASFI | 148 | 3.6 (2.4) | 3.8 (2.5) | 0.54 |
BASMI | 141 | 1.2 (1.1) | 1.4 (1.2) | 0.42 |
EQ-5D | 141 | 54.8 (22.8) | 55.8 (18.3) | 0.79 |
Current periph. Arthritis,% | 159 | 41.6 | 52.4 | 0.20 |
Number of swollen joints | 155 | 0.7 (1.2) | 1.3 (2.5) | 0.32 |
Current enthesitis, % | 158 | 80.5 | 85.2 | 0.53 |
Modified MASES | 157 | 2.3 (2.5) | 3.9 (3.3) | 0.002 |
Dactylitis ever, % | 161 | 13.2 | 21.2 | 0.21 |
csDMARDs ever, % | 163 | 26.9 | 41.2 | 0.07 |
Taking NSAIDs, % | 150 | 92.9 | 86.2 | 0.29 |
Current smoking, % | 139 | 28.3 | 22.8 | 0.55 |
Body mass index | 160 | 25.9 (4.2) | 24.0 (4.4) | < 0.001 |
Type of TNFi, % | 163 | 0.25 | ||
• Adalimumab | 34.6 | 45.9 | ||
• Certolizumab | 1.3 | 0.0 | ||
• Etanercept | 19.2 | 15.3 | ||
• Golimumab | 20.5 | 24.7 | ||
• Infliximab | 24.4 | 14.1 |